INmune Bio (NASDAQ:INMB) Rating Increased to Strong-Buy at RODMAN&RENSHAW

INmune Bio (NASDAQ:INMB) was upgraded by stock analysts at RODMAN&RENSHAW to a “strong-buy” rating in a research note issued on Tuesday,Zacks.com reports.

INMB has been the topic of several other research reports. Alliance Global Partners began coverage on shares of INmune Bio in a report on Monday, October 21st. They issued a “buy” rating and a $20.00 target price on the stock. Rodman & Renshaw assumed coverage on shares of INmune Bio in a research note on Tuesday. They issued a “buy” rating and a $23.00 price target on the stock. Four research analysts have rated the stock with a buy rating and one has issued a strong buy rating to the company. According to MarketBeat.com, INmune Bio currently has a consensus rating of “Buy” and an average target price of $20.75.

INmune Bio Stock Performance

Shares of INMB stock opened at $8.02 on Tuesday. The stock has a fifty day simple moving average of $5.44 and a two-hundred day simple moving average of $6.04. The firm has a market capitalization of $177.80 million, a PE ratio of -3.68 and a beta of 1.78. INmune Bio has a 52-week low of $4.32 and a 52-week high of $14.74.

INmune Bio (NASDAQ:INMB) last released its earnings results on Thursday, October 31st. The company reported ($0.60) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.49) by ($0.11). During the same period in the previous year, the firm posted ($0.48) earnings per share. On average, sell-side analysts forecast that INmune Bio will post -2.24 EPS for the current fiscal year.

Institutional Inflows and Outflows

A number of hedge funds have recently modified their holdings of the business. Praetorian PR LLC boosted its holdings in INmune Bio by 61.0% during the 3rd quarter. Praetorian PR LLC now owns 780,800 shares of the company’s stock valued at $4,209,000 after acquiring an additional 295,800 shares during the period. Marshall Wace LLP boosted its stake in shares of INmune Bio by 332.1% during the second quarter. Marshall Wace LLP now owns 115,916 shares of the company’s stock valued at $1,022,000 after purchasing an additional 89,091 shares during the period. State Street Corp grew its holdings in shares of INmune Bio by 35.1% in the third quarter. State Street Corp now owns 226,428 shares of the company’s stock worth $1,220,000 after purchasing an additional 58,838 shares during the last quarter. XTX Topco Ltd bought a new position in shares of INmune Bio in the third quarter worth about $249,000. Finally, Westside Investment Management Inc. increased its stake in INmune Bio by 57.3% in the 3rd quarter. Westside Investment Management Inc. now owns 71,315 shares of the company’s stock worth $384,000 after buying an additional 25,975 shares during the period. Institutional investors own 12.72% of the company’s stock.

INmune Bio Company Profile

INmune Bio, Inc, a clinical-stage immunology company, focuses on developing drugs to reprogram the patients innate immune system to treat disease in the United States. It intends to develop and commercialize product candidates to treat hematologic malignancies, solid tumors, and chronic inflammation.